Ads
related to: digoxin fab antibody treatment side effects for bladder cancer- Clinical Trial Data
View Clinical Trial Results
And See Efficacy Data.
- Important Safety Info
See Safety Info & Learn
About Adverse Reactions.
- Clinical Trial Data
Search results
Results From The WOW.Com Content Network
Digoxin immune fab or digoxin-specific antibody is an antidote for overdose of digoxin. [3] It is made from immunoglobulin fragments from sheep that have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind (GlaxoSmithKline) and DigiFab (BTG plc).
The primary treatment of digoxin toxicity is digoxin immune fab, which is an antibody made up of anti-digoxin immunoglobulin fragments. This antidote has been shown to be highly effective in treating life-threatening signs of digoxin toxicity such as hyperkalemia, hemodynamic instability, and arrhythmias. [11] Fab dose can be determined by two ...
An unusual side effect of digoxin is a disturbance of color vision (mostly yellow and green) called xanthopsia. Vincent van Gogh's "Yellow Period" may have somehow been influenced by concurrent digitalis therapy. Other oculotoxic effects of digoxin include generalized blurry vision, as well as seeing a "halo" around each point of light.
Digoxin Immune Fab is the antigen binding fragment of polyclonal antibodies raised to Digitalis derivative as a hapten bound to a protein and is used for the reversal of life-threatening digoxin or digitoxin toxicity. [1] [2] [3] Rho(D) immune globulin is made from pooled human plasma provided by Rh-negative donors with antibodies to the D antigen.
Digoxin is taken by mouth or by injection into a vein. [4] Digoxin has a half life of approximately 36 hours given at average doses in patients with normal renal function. It is excreted mostly unchanged in the urine. Common side effects include breast enlargement with other side effects generally due to an excessive dose.
Passive antibody administration has become a widely approved cancer treatment following the development of monoclonal antibody (mAb). Since these antibodies originated from mice, they were wrought with problems of immunogenetics and poor abilities to induce an immune response in the human body, limiting their clinical applicability. [12]